Sunshine Biopharma (NASDAQ:SBFM – Get Rating) and SomaLogic (NASDAQ:SLGC – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
This is a breakdown of recent recommendations for Sunshine Biopharma and SomaLogic, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SomaLogic has a consensus target price of $10.67, suggesting a potential upside of 361.76%. Given SomaLogic’s higher possible upside, analysts plainly believe SomaLogic is more favorable than Sunshine Biopharma.
Insider & Institutional Ownership
Valuation and Earnings
This table compares Sunshine Biopharma and SomaLogic’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sunshine Biopharma||$230,000.00||85.44||-$12.44 million||N/A||N/A|
|SomaLogic||$81.63 million||5.19||-$87.55 million||($0.46)||-5.02|
Sunshine Biopharma has higher earnings, but lower revenue than SomaLogic.
This table compares Sunshine Biopharma and SomaLogic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
SomaLogic beats Sunshine Biopharma on 6 of the 10 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.